Not available
Quote | Regulus Therapeutics Inc. (NASDAQ:RGLS)
Last: | $1.66 |
---|---|
Change Percent: | -0.56% |
Open: | $1.81 |
Close: | $1.66 |
High: | $1.81 |
Low: | $1.62 |
Volume: | 684,200 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Regulus Therapeutics Inc. (NASDAQ:RGLS)
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Message Board Posts | Regulus Therapeutics Inc. (NASDAQ:RGLS)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $RGLS 35% v1,4M c1.22 f16,840M H1.3499 ML.76 RL.88 | znewcar1 | investorshangout | 04/13/2023 9:17:51 PM |
I took a much larger position after $RGLS | jimmy667 | investorshub | 09/15/2022 2:28:08 AM |
Hi Jimmy, yes I agree. Investors starting to | subslover | investorshub | 09/14/2022 8:26:12 AM |
very strong clinical science | jimmy667 | investorshub | 09/14/2022 5:08:59 AM |
Very strong today! | subslover | investorshub | 09/12/2022 1:47:25 PM |
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...